Log in

NASDAQ:PDLI - PDL BioPharma Stock Price, Forecast & News

$3.67
-0.03 (-0.81 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$3.67
Now: $3.67
$3.78
50-Day Range
$3.07
MA: $3.30
$3.74
52-Week Range
$2.06
Now: $3.67
$3.89
Volume883,804 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PDL BioPharma, Inc acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:PDLI
CUSIP69329Y10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees105
Next Earnings Date3/12/2020 (Estimated)
OptionableOptionable

Receive PDLI News and Ratings via Email

Sign-up to receive the latest news and ratings for PDLI and its competitors with MarketBeat's FREE daily newsletter.


PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions

What is PDL BioPharma's stock symbol?

PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."

How will PDL BioPharma's stock buyback program work?

PDL BioPharma announced that its board has approved a share buyback plan on Monday, September 24th 2018, which allows the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 27.3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its shares are undervalued.

How were PDL BioPharma's earnings last quarter?

PDL BioPharma Inc (NASDAQ:PDLI) released its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported $0.10 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.04. The biotechnology company had revenue of $46.58 million for the quarter. View PDL BioPharma's Earnings History.

When is PDL BioPharma's next earnings date?

PDL BioPharma is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for PDL BioPharma.

What price target have analysts set for PDLI?

1 brokers have issued twelve-month target prices for PDL BioPharma's stock. Their forecasts range from $3.00 to $3.00. On average, they expect PDL BioPharma's share price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 18.3%. View Analyst Price Targets for PDL BioPharma.

What is the consensus analysts' recommendation for PDL BioPharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.

Has PDL BioPharma been receiving favorable news coverage?

News articles about PDLI stock have been trending somewhat positive on Sunday, InfoTrie reports. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. PDL BioPharma earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for PDL BioPharma.

Are investors shorting PDL BioPharma?

PDL BioPharma saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 10,150,000 shares, a decrease of 27.3% from the December 31st total of 13,960,000 shares. Based on an average trading volume of 1,320,000 shares, the days-to-cover ratio is presently 7.7 days. Approximately 9.1% of the shares of the company are sold short. View PDL BioPharma's Current Options Chain.

Who are some of PDL BioPharma's key competitors?

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), Opko Health (OPK), Advanced Micro Devices (AMD), Novavax (NVAX), Canopy Growth (CGC), Teva Pharmaceutical Industries (TEVA), General Electric (GE), Bank of America (BAC), NovaBay Pharmaceuticals (NBY) and Cara Therapeutics (CARA).

Who are PDL BioPharma's key executives?

PDL BioPharma's management team includes the folowing people:
  • Mr. Dominique P. Monnet, CEO, Pres & Director (Age 58)
  • Mr. Peter S. Garcia, VP & CFO (Age 57)
  • Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 55)
  • Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.

Who are PDL BioPharma's major shareholders?

PDL BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.16%), Engine Capital Management LP (5.43%), Brandes Investment Partners LP (5.09%), Connor Clark & Lunn Investment Management Ltd. (3.51%), Charles Schwab Investment Management Inc. (3.04%) and State Street Corp (2.90%). View Institutional Ownership Trends for PDL BioPharma.

Which major investors are selling PDL BioPharma stock?

PDLI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, UBS Group AG, Goldman Sachs Group Inc., Connor Clark & Lunn Investment Management Ltd., Chicago Equity Partners LLC, State Board of Administration of Florida Retirement System, SG Americas Securities LLC and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for PDL BioPharma.

Which major investors are buying PDL BioPharma stock?

PDLI stock was acquired by a variety of institutional investors in the last quarter, including Engine Capital Management LP, Ancora Advisors LLC, Context Capital Management LLC, AQR Capital Management LLC, Brandes Investment Partners LP, Thrivent Financial for Lutherans, Caxton Associates LP and Bank of Montreal Can. View Insider Buying and Selling for PDL BioPharma.

How do I buy shares of PDL BioPharma?

Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PDL BioPharma's stock price today?

One share of PDLI stock can currently be purchased for approximately $3.67.


MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  450 (Vote Underperform)
Total Votes:  656
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel